Incyte Corporation

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
45337C102
SEDOL
BYZH6X8
CIK
0000879169
www.incyte.com
LEI:
©
FIGI: BBG000BNPSQ9
INCY
Incyte Corporation
GICS: - · Sector: Healthcare · Sub-Sector: Biotechnology
AI
PROFILER
NAME
Incyte Corporation
ISIN
US45337C1027
TICKER
INCY
MIC
XNAS
REUTERS
INCY.OQ
BLOOMBERG
INCY US
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
TradingView ActivTrader MT4 MT5
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Tue, 17.12.2024       Incyte
US45337C1027

Incyte (Nasdaq: INCY) announced today that it will present at the 43rd Annual J. P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 am (PST). The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mis...
Read More
Incyte
Technical Analysis Termsheet Terminal
Permalink
Tue, 10.12.2024       Incyte
US45337C1027

Incyte (Nasdaq:INCY) today announced additional results from the pivotal Phase 3 inMIND trial evaluating treatment with tafasitamab (Monjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, in combination with lenalidomide and rituximab compared with placebo plus lenalidomide and rituximab in patients with relapsed or refra...
Read More
Incyte
Technical Analysis Termsheet Terminal
Permalink
Sat, 07.12.2024       Incyte
US45337C1027

Incyte (Nasdaq:INCY) today announced results from the Phase 3 POD1UM-304 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with platinum-based chemotherapy for the treatment of adults with previously untreated non-squamous and squamous metastatic non-small cell lung cancer ...
Read More
Incyte
Technical Analysis Termsheet Terminal
Permalink
Fri, 06.12.2024       Incyte
US45337C1027

Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 7,259 shares of the Company’s common stock to 15 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of December 2, 2024, and were approved b...
Read More
Incyte
Technical Analysis Termsheet Terminal
Permalink
Tue, 26.11.2024       Incyte
US45337C1027

Incyte (Nasdaq:INCY) announced today that it will now present at Citi’s 2024 Global Healthcare Conference on Tuesday, December 3, 2024 at 8:00 a.m. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solv...
Read More
Incyte
Technical Analysis Termsheet Terminal
Permalink
Mon, 25.11.2024       Incyte
US45337C1027

Incyte (Nasdaq: INCY) today announced that the Company will present new data from across its oncology portfolio at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego. “These data illustrate our innovative approach that aims to identify new and best-in-class treatments for patients with a range of cancers,” said Pablo J. Ca...
Read More
Incyte
Technical Analysis Termsheet Terminal
Permalink
Mon, 18.11.2024       Incyte
US45337C1027

Incyte (Nasdaq:INCY) today announced that it will pause enrollment in the ongoing Phase 2 study of MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU). The decision was made following the observation of certain in vivo preclinical toxicology findings. These data have been shared with the U.S. Food and Drug Administration (FDA) and Incyte...
Read More
Incyte
Technical Analysis Termsheet Terminal
Permalink
Thu, 14.11.2024       Incyte
US45337C1027

Incyte (Nasdaq: INCY) announced today that it will present at Citi’s 2024 Global Healthcare Conference on Tuesday, December 3, 2024 at 3:15 p.m. in Miami. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to ...
Read More
Incyte
Technical Analysis Termsheet Terminal
Permalink
Thu, 07.11.2024       Incyte
US45337C1027

Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 33,003 shares of the Company’s common stock and stock option awards to purchase an aggregate of 15,812 shares of the Company’s common stock to 27 new employees. The awards were made under the Company’s 2024 Inducement Stock Incenti...
Read More
Incyte
Technical Analysis Termsheet Terminal
Permalink
Wed, 30.10.2024       Incyte
US45337C1027

Incyte (Nasdaq: INCY) announced today that it will present at the following investor conferences during the month of November: Guggenheim’s Inaugural Healthcare Innovation Conference on Monday, November 11, 2024 at 2:00 pm (EST) Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 9:30 am (GMT) The presentations will be we...
Read More
Incyte
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S